The reality of a sickle cell disease cure brings fear, optimism, and questions to patients’ lives; veterans who are in suicidal crisis can receive free emergency care at any Department of Veterans Affairs or private facility; Pfizer to increase access to progressive treatments through sale of drugs at non-profit prices to poor countries.
Forthcoming Sickle Cell Cure Elicits Complex Emotions
As soon as this year, a gene therapy that is essentially a cure for sickle cell disease might become available, reports The New York Times. FDA approval is being sought by 2 drug companies for gene therapies. Clinical trials have included one gene therapy drug from bluebird bio and another from Vertex and CRISPR Therapeutics that have eliminated pain episodes experienced by people with sickle cell disease. Current sufferers of the disease report a range of feelings, like concern for the link between sickle cell disease and their identity, the financial and logistical barriers to getting the treatment, and the optimistic hope that it will improve their lives.
Veterans in Suicidal Crisis Now Eligible for Free Care
Starting today, US military veterans experiencing suicidal crisis can receive free emergency medical care at any Veterans Affairs (VA) or private facility, even if they aren’t enrolled in the VA system, according to NBC News. Up to 30 days of inpatient or crisis residential care will be covered, and up to 90 days of follow-up outpatient care. Over 18 million US veterans might be eligible. The policy will be broadcasted by the VA on Friday. The hope is that if financial burden is reduced, that this care can save veterans’ lives.
Pfizer to Sell Drugs at Non-Profit Price in Low-Income Countries
US drug manufacturer Pfizer Inc. reported today that it will make its complete drug portfolio available on a not-for-profit basis to 45 low-income countries worldwide, announced Reuters. Drugs offered include off-patent medications like chemotherapies and oral cancer treatments. This declaration is an extension of company program “An Accord for a Healthier World” that is intended to expand access to advanced treatments in some of the most impoverished countries globally.
First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA
December 23rd 2024The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with inhibitors by preventing or reducing bleeding episodes in adults and children 12 years and older.
Read More
Top 5 Most-Read Articles on Rare Blood Disorders in 2024
December 20th 2024Key findings from 2024 focused on conditions like vaccine-induced immune thrombotic thrombocytopenia, immune thrombocytopenia, and hemophilia, stressing the importance of early detection and innovative therapies.
Read More
Unmet Needs in Hemophilia: Prophylaxis, Bleeding, Quality of Life
December 12th 2024A pair of studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition highlight continuing gaps in hemophilia care despite the availability of prophylactic therapies.
Read More
Rare Blood Disease Innovations Address Unmet Needs, According to ASH Data
December 11th 2024Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, with key research presented on immune thrombocytopenia, hemophilia, and multiple myeloma.
Read More
New Data Reinforce Iptacopan's Role in Transforming PNH Care With Hemoglobin, QOL Gains
December 6th 2024Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan (Fabhalta) as a twice-daily oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who transitioned from anti-C5 therapies.
Read More